The Priority Review

Tag

ranibizumab

1 story

  1. Approvals

    CHMP adopts positive opinion on Fovlussea

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending a marketing authorisation for Fovlussea, a ranibizumab biosimilar for several retinal conditions. The applicant is Accord Healthcare S.L.U., and the product will be available as a 10 mg/ml solution for injection.